PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has announced a key addition to its Board of Directors with the appointment of Sohanya Cheng, effective October 31, 2024. Concurrently, Michael Torok has stepped down from his board position due to other professional obligations.
Sanford Zweifach, Chair of the Carisma Board, expressed enthusiasm for Cheng’s appointment, stating, “It’s a pleasure to welcome Sohanya to our Board. Her broad experience in oncology, alongside her skills in leadership, strategic planning, and commercialization, will be instrumental as we continue to advance our portfolio and strengthen our foundation. We are also thankful to Michael for his valuable service and wish him all the best in his next chapter.”
Cheng brings a wealth of expertise in oncology and strategic business management, which Carisma sees as vital as it continues to develop its pipeline of immunotherapies. Her role is expected to enhance the company’s strategic direction, particularly in solidifying its position as a leader in engineered macrophages within the oncology sector.
In joining the board, Cheng remarked, “I am excited to join Carisma’s Board and collaborate with the management team as the Company advances its mission to deliver innovative immunotherapies to patients facing serious diseases. I look forward to sharing my insights and supporting the Company’s strategic goals as it solidifies its position as a leader in engineered macrophages within oncology and beyond.”
This strategic board change highlights Carisma Therapeutics’ efforts to drive innovation and leadership in the field of oncology, leveraging Cheng’s experience to enhance its mission and impact in the industry.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.